- C108P: Rovalpituzumab Biosimilar, DLL3 Monoclonal Antibody - Recombinant Humanized IgG1 Monoclonal Antibody. 
 Specificity/Sensitivity: The research grade rovalpituzumab biosimilar specifically binds to the DLL3 protein.
 Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by rovalpituzumab.